Gqg Partners LLC Genmab A/S Transaction History

Gqg Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $514,877 - $676,360	-14,354 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$32.88 - $44.57 $108,273 - $146,769	3,293 Added 29.77%	14,354 $586,000
Q1 2021 May 14, 2021	SELL	$30.92 - $44.4 $246,896 - $354,534	-7,985 Reduced 41.92%	11,061 $363,000
Q4 2020 Feb 12, 2021	BUY	$33.66 - $40.76 $37,598 - $45,528	1,117 Added 6.23%	19,046 $774,000
Q3 2020 Nov 13, 2020	BUY	$33.07 - $38.68 $3,571 - $4,177	108 Added 0.61%	17,929 $656,000
Q2 2020 Aug 19, 2020	SELL	$20.05 - $33.89 $1.69 Million - $2.86 Million	-84,285 Reduced 82.55%	17,821 $604,000
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $1.86 Million - $3.14 Million	92,594 Added 973.44%	102,106 $28.8 Million
Q4 2019 Feb 13, 2020	BUY	$18.88 - $24.14 $179,586 - $229,619	9,512 New	9,512 $212,000

248

61.3M

159K

38K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.7B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Gqg Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Gqg Partners LLC with notifications on news.